Astec LifeSciences Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Astec LifeSciences de 112.2% y 34.3% respectivamente, mientras que el BPA crecerá en un 112.2% al año.

Información clave

92.9%

Tasa de crecimiento de los beneficios

93.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Chemicals	20.7%
Tasa de crecimiento de los ingresos	63.1%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	09 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Astec LifeSciences Limited (NSE:ASTEC) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable

Mar 15

Astec LifeSciences (NSE:ASTEC) Could Be Struggling To Allocate Capital

May 17

Shareholders Are Optimistic That Astec LifeSciences (NSE:ASTEC) Will Multiply In Value

Oct 14

We Ran A Stock Scan For Earnings Growth And Astec LifeSciences (NSE:ASTEC) Passed With Ease

Jul 27

Here's Why Astec LifeSciences (NSE:ASTEC) Can Manage Its Debt Responsibly

Jun 28

A Look At The Intrinsic Value Of Astec LifeSciences Limited (NSE:ASTEC)

Jun 03

Analysts Just Published A Bright New Outlook For Astec LifeSciences Limited's (NSE:ASTEC)

May 08

Astec LifeSciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 06

Why We Like The Returns At Astec LifeSciences (NSE:ASTEC)

Jan 25

Is Astec LifeSciences (NSE:ASTEC) A Risky Investment?

Dec 13

We Take A Look At Why Astec LifeSciences Limited's (NSE:ASTEC) CEO Has Earned Their Pay Packet

Jul 21

Does Astec LifeSciences (NSE:ASTEC) Have A Healthy Balance Sheet?

May 02

The Trend Of High Returns At Astec LifeSciences (NSE:ASTEC) Has Us Very Interested

Apr 17

Do Astec LifeSciences's (NSE:ASTEC) Earnings Warrant Your Attention?

Apr 02

Is Astec LifeSciences Limited's (NSE:ASTEC) Shareholder Ownership Skewed Towards Insiders?

Mar 18

Declining Stock and Solid Fundamentals: Is The Market Wrong About Astec LifeSciences Limited (NSE:ASTEC)?

Jan 28

What Does Astec LifeSciences Limited's (NSE:ASTEC) Share Price Indicate?

Jan 17

Why We Like The Returns At Astec LifeSciences (NSE:ASTEC)

Jan 08

I Ran A Stock Scan For Earnings Growth And Astec LifeSciences (NSE:ASTEC) Passed With Ease

Dec 28

Is Astec LifeSciences Limited (NSE:ASTEC) Popular Amongst Insiders?

Dec 18

Astec LifeSciences (NSE:ASTEC) Is Growing Earnings But Are They A Good Guide?

Dec 07

Does Astec LifeSciences (NSE:ASTEC) Have A Healthy Balance Sheet?

Nov 27

Ashok Hiremath Is The MD & Director of Astec LifeSciences Limited (NSE:ASTEC) And They Just Sold 35% Of Their Shares

Nov 17

Previsiones de crecimiento de beneficios e ingresos

NSEI:ASTEC - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2026	8,716	931	N/A	1,561	1
3/31/2025	6,756	579	N/A	813	1
3/31/2024	1,558	-10	-1,253	102	N/A
12/31/2023	4,317	-509	N/A	N/A	N/A
9/30/2023	4,981	-258	-1,580	101	N/A
6/30/2023	5,871	60	N/A	N/A	N/A
3/31/2023	6,285	256	-426	747	N/A
12/31/2022	7,735	736	N/A	N/A	N/A
9/30/2022	8,297	975	-448	351	N/A
6/30/2022	7,325	883	N/A	N/A	N/A
3/31/2022	6,769	899	-804	236	N/A
12/31/2021	5,803	708	N/A	N/A	N/A
9/30/2021	5,230	531	-800	483	N/A
6/30/2021	5,754	619	N/A	N/A	N/A
3/31/2021	5,587	650	-1,107	-82	N/A
12/31/2020	5,698	723	N/A	N/A	N/A
9/30/2020	5,786	774	1,190	1,885	N/A
6/30/2020	5,639	648	N/A	N/A	N/A
3/31/2020	5,287	475	1,231	1,684	N/A
12/31/2019	4,844	291	N/A	N/A	N/A
9/30/2019	4,781	269	-420	32	N/A
6/30/2019	4,507	331	N/A	N/A	N/A
3/31/2019	4,382	357	-375	153	N/A
12/31/2018	4,246	402	N/A	N/A	N/A
9/30/2018	3,781	374	N/A	N/A	N/A
6/30/2018	3,611	325	N/A	N/A	N/A
3/31/2018	3,676	349	150	647	N/A
12/31/2017	3,254	212	N/A	N/A	N/A
9/30/2017	3,119	148	N/A	N/A	N/A
6/30/2017	3,008	192	N/A	N/A	N/A
3/31/2017	2,987	191	N/A	192	N/A
12/31/2016	3,167	-29	N/A	N/A	N/A
9/30/2016	2,865	-114	N/A	N/A	N/A
6/30/2016	2,643	-206	N/A	N/A	N/A
3/31/2016	2,330	50	N/A	-125	N/A
12/31/2015	2,629	-115	N/A	N/A	N/A
9/30/2015	2,777	61	N/A	N/A	N/A
6/30/2015	2,728	84	N/A	N/A	N/A
3/31/2015	2,669	148	N/A	75	N/A
12/31/2014	2,212	131	N/A	N/A	N/A
9/30/2014	2,147	127	N/A	N/A	N/A
6/30/2014	2,156	96	N/A	N/A	N/A
3/31/2014	2,070	87	N/A	146	N/A
12/31/2013	2,179	97	N/A	N/A	N/A
9/30/2013	2,076	76	N/A	N/A	N/A
6/30/2013	1,849	72	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ASTEC sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (6.7%).

Beneficios vs. Mercado: Se prevé que ASTEC sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que ASTEC sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (34.3% al año) de ASTEC crezcan más rápidamente que los del mercado Indian (10.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (34.3% al año) de ASTEC crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de ASTEC se prevé que sea elevada dentro de 3 años.

Astec LifeSciences Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 14% to ₹1,108

Price target decreased by 9.3% to ₹1,205

Price target decreased to ₹1,923

Price target increased to ₹2,132

Price target increased to ₹1,869

Consensus revenue estimates increase by 11%

Recent updates

Astec LifeSciences Limited, Annual General Meeting, Jul 29, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Astec Lifesciences Limited Announces Resignation of Mr. K. Suryanarayan as Chief Financial Officer, Effective May 3, 2024

Astec LifeSciences Limited to Report Q4, 2024 Results on May 02, 2024

Price target decreased by 14% to ₹1,108

Astec LifeSciences Limited (NSE:ASTEC) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable

Price target decreased by 9.3% to ₹1,205

Third quarter 2024 earnings released: ₹12.41 loss per share (vs ₹0.43 profit in 3Q 2023)

Astec LifeSciences Limited to Report Q3, 2024 Results on Jan 25, 2024

Second quarter 2024 earnings released: ₹6.85 loss per share (vs ₹9.34 profit in 2Q 2023)

Astec LifeSciences Limited to Report Q2, 2024 Results on Oct 27, 2023

Astec LifeSciences Limited Declares Final Dividend for the Financial Year Ended March 31, 2023

Astec LifeSciences Limited to Report Q1, 2024 Results on Jul 27, 2023

Upcoming dividend of ₹1.50 per share at 0.1% yield

Full year 2023 earnings released: EPS: ₹13.04 (vs ₹45.87 in FY 2022)

Non-Executive Non-Independent Director recently sold ₹4.8m worth of stock

Astec LifeSciences (NSE:ASTEC) Could Be Struggling To Allocate Capital

Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable by August 1, 2023

Full year 2023 earnings released: EPS: ₹13.04 (vs ₹45.87 in FY 2022)

Investor sentiment improves as stock rises 23%

Third quarter 2023 earnings released: EPS: ₹0.43 (vs ₹12.63 in 3Q 2022)

Astec LifeSciences Limited to Report Q3, 2023 Results on Jan 30, 2023

Price target decreased to ₹1,923

High number of new directors

Second quarter 2023 earnings released: EPS: ₹9.34 (vs ₹4.63 in 2Q 2022)

Astec Lifesciences Limited Announces Appointment of Mr. Madhur Gundecha as the Chief Financial Officer

Astec LifeSciences Limited to Report Q2, 2023 Results on Oct 28, 2022

Investor sentiment improved over the past week

Shareholders Are Optimistic That Astec LifeSciences (NSE:ASTEC) Will Multiply In Value

Astec LifeSciences Limited Announces the Resignation of Saurav Bhala as Chief Financial Officer

Price target increased to ₹2,132

High number of new directors

We Ran A Stock Scan For Earnings Growth And Astec LifeSciences (NSE:ASTEC) Passed With Ease

Astec Lifesciences Limited Appoints Burjis Godrej as an Additional, Non-Executive, Non- Independent Director

Astec LifeSciences Limited to Report Q1, 2023 Results on Jul 25, 2022

Upcoming dividend of ₹1.50 per share

Full year 2022 earnings: Revenues exceed analyst expectations

Here's Why Astec LifeSciences (NSE:ASTEC) Can Manage Its Debt Responsibly

A Look At The Intrinsic Value Of Astec LifeSciences Limited (NSE:ASTEC)

Price target increased to ₹1,869

Consensus revenue estimates increase by 11%

Analysts Just Published A Bright New Outlook For Astec LifeSciences Limited's (NSE:ASTEC)

Astec LifeSciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

MD & Director recently bought ₹37m worth of stock

Astec LifeSciences Limited Announces Cessation of Ashok Hiremath as the Managing Director of the Company

Non-Executive Non-Independent Director recently bought ₹1.5m worth of stock

Non-Executive Non-Independent Director recently bought ₹3.5m worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Why We Like The Returns At Astec LifeSciences (NSE:ASTEC)

Insider recently sold ₹1.5m worth of stock

Insider recently sold ₹1.5m worth of stock

Is Astec LifeSciences (NSE:ASTEC) A Risky Investment?

Investor sentiment improved over the past week

Insider recently sold ₹2.4m worth of stock

Price target increased to ₹1,508

Price target increased to ₹1,386

We Take A Look At Why Astec LifeSciences Limited's (NSE:ASTEC) CEO Has Earned Their Pay Packet

Upcoming dividend of ₹1.50 per share

Full year 2021 earnings released: EPS ₹33.23 (vs ₹24.29 in FY 2020)

Whole Time Director recently sold ₹2.9m worth of stock

Investor sentiment improved over the past week

MD & Director recently sold ₹240m worth of stock

Does Astec LifeSciences (NSE:ASTEC) Have A Healthy Balance Sheet?

Full year 2021 earnings released: EPS ₹33.23 (vs ₹24.29 in FY 2020)

Astec Lifesciences Limited Recommends Final Dividend for the Year Ended March 31, 2021, Payable on August 6, 2021

Price target decreased to ₹1,221